SCHEMBL6300196

SCHEMBL6300196

CC(C)(C)OC(=O)n1nc(/C=C/C(=O)O)c2cc(NS(=O)(=O)c3ccccc3S(C)(=O)=O)ccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.38
MAP2K4 P45985 1/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
THRB P10828 1/20 0.34
HTT P42858 1/20 0.34
ALDH1A1 P00352 1/20 0.33
ATM Q13315 1/20 0.33
TGFBR1 P36897 1/20 0.33
HPGD P15428 1/20 0.33
PKM P14618 1/20 0.32
PTGDR2 Q9Y5Y4 2/20 0.32
ACLY P53396 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6300200 1.00 NR1H2 (0.38) NR1H2MAP2K4MEN1KMT2ALMNA
SCHEMBL4006966 0.92 NR1H2 (0.36) NR1H2MAP2K4MEN1KMT2ALMNA
SCHEMBL4006971 0.87 NR1H2 (0.38) NR1H2MAP2K4MEN1KMT2ALMNA
SCHEMBL4006969 0.87 NR1H2 (0.38) NR1H2MAP2K4MEN1KMT2ALMNA
SCHEMBL4010828 0.84 NR1H2 (0.40) NR1H2MAP2K4MEN1KMT2ALMNA
SCHEMBL4008201 0.83 NR1H2 (0.39) NR1H2MAP2K4MEN1KMT2ALMNA
SCHEMBL1461078 0.74 AURKA (0.52) MAPT
SCHEMBL1461080 0.74 AURKA (0.52) MAPT
Hydrochloric Acid SCHEMBL4152154 0.73 AURKA (0.51) MAPT
SCHEMBL4014346 0.73 MAPT (0.42) NR1H2MAP2K4MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6858638-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-02-22 US disclosed
EP-1487803-A1 INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY Aventis Pharma S.A. (FR) 2004-12-22 EP disclosed
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2004-06-03 US disclosed
WO-2003078402-A1 INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY AVENTIS PHARMA S.A. (FR) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 NR1H2 3796/4885MAP2K4 340/4885MEN1 2247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.